How Is Revvity's Stock Performance Compared to Other Health Care Stocks?

Group 1 - Revvity, Inc. (RVTY) is a leading provider of health sciences solutions with a market cap of $11.4 billion, focusing on multi-omics technologies and diagnostic services [1][2] - RVTY is classified as a large-cap stock, highlighting its size and influence in the diagnostics and research industry, supported by strengths such as diversification, scale, and technological capabilities [2] - Despite a 21.7% decline from its 52-week high of $128.29, RVTY stock has gained 21.3% over the past three months, outperforming the Health Care Select Sector SPDR Fund's (XLV) 11.6% gains [3][4] Group 2 - Over the longer term, RVTY shares rose 5% over six months but fell 13.4% over the past 52 weeks, underperforming XLV's six-month gains of 12.6% and 9.3% returns over the last year [4] - RVTY reported Q3 results with revenue of $7 billion, a year-over-year increase of 2.2%, while adjusted EPS decreased by 7.8% to $1.18 [5] - Wall Street analysts maintain a "Moderate Buy" rating for RVTY, with a mean price target of $112.53 indicating a potential upside of 12% from current levels [6]